<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>67</volume><submitter>Sebbag C</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>To compare the prevalence of contraception in breast cancer (BC) patients at risk of unintentional pregnancy (i.e. not currently pregnant or trying to get pregnant) and matched controls.&lt;h4>Study design&lt;/h4>The FEERIC study (Fertility, Pregnancy, Contraception after BC in France) is a prospective, multicenter case-control study, including localized BC patients aged 18-43 years, matched for age and parity to cancer-free volunteer controls in a 1:2 ratio. Data were collected through online questionnaires completed on the Seintinelles research platform.&lt;h4>Results&lt;/h4>In a population of 1278 women at risk of unintentional pregnancy, the prevalence of contraception at study inclusion did not differ significantly between cases (340/431, 78.9%) and controls (666/847, 78.6%, p =</pubmed_abstract><journal>Breast (Edinburgh, Scotland)</journal><pagination>62-70</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9982267</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network).</pubmed_title><pmcid>PMC9982267</pmcid><pubmed_authors>Hotton J</pubmed_authors><pubmed_authors>Coussy F</pubmed_authors><pubmed_authors>Maitrot-Mantelet L</pubmed_authors><pubmed_authors>Giacchetti S</pubmed_authors><pubmed_authors>Decanter C</pubmed_authors><pubmed_authors>Espie M</pubmed_authors><pubmed_authors>Dumas E</pubmed_authors><pubmed_authors>Darrigues L</pubmed_authors><pubmed_authors>Gompel A</pubmed_authors><pubmed_authors>Asselain B</pubmed_authors><pubmed_authors>Hamy AS</pubmed_authors><pubmed_authors>Plu-Bureau G</pubmed_authors><pubmed_authors>Brain E</pubmed_authors><pubmed_authors>Garin C</pubmed_authors><pubmed_authors>Laot L</pubmed_authors><pubmed_authors>Sebbag C</pubmed_authors><pubmed_authors>Santulli P</pubmed_authors><pubmed_authors>Sablone L</pubmed_authors><pubmed_authors>Bobrie A</pubmed_authors><pubmed_authors>Labrosse J</pubmed_authors><pubmed_authors>Ray-Coquard I</pubmed_authors><pubmed_authors>Mailliez A</pubmed_authors><pubmed_authors>Seintinelles RN</pubmed_authors><pubmed_authors>Rousset-Jablonski C</pubmed_authors><pubmed_authors>Evrevin C</pubmed_authors><pubmed_authors>Senechal-Davin C</pubmed_authors><pubmed_authors>Guerin J</pubmed_authors><pubmed_authors>Reyal F</pubmed_authors><pubmed_authors>Cessot M</pubmed_authors><pubmed_authors>Coutant C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network).</name><description>&lt;h4>Objective&lt;/h4>To compare the prevalence of contraception in breast cancer (BC) patients at risk of unintentional pregnancy (i.e. not currently pregnant or trying to get pregnant) and matched controls.&lt;h4>Study design&lt;/h4>The FEERIC study (Fertility, Pregnancy, Contraception after BC in France) is a prospective, multicenter case-control study, including localized BC patients aged 18-43 years, matched for age and parity to cancer-free volunteer controls in a 1:2 ratio. Data were collected through online questionnaires completed on the Seintinelles research platform.&lt;h4>Results&lt;/h4>In a population of 1278 women at risk of unintentional pregnancy, the prevalence of contraception at study inclusion did not differ significantly between cases (340/431, 78.9%) and controls (666/847, 78.6%, p =</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-26T07:39:10.264Z</modification><creation>2024-10-18T20:34:25.964Z</creation></dates><accession>S-EPMC9982267</accession><cross_references><pubmed>36630821</pubmed><doi>10.1016/j.breast.2022.12.033</doi></cross_references></HashMap>